The Youth Opioid Recovery Support (YORS) intervention is a novel treatment for young adults with opioid use disorder (OUD) that uses developmentally informed strategies to reduce barriers engagement. YORS strategies, such as home delivery of extended-release buprenorphine and naltrexone OUD, are designed increase engagement in treatment, but the COVID-19 pandemic these risk virus exposure sprea...

Carbamazepine (CBZ) has long been a therapeutic option for bipolar disorder. Carbamazepine extended-release capsules (CBZ-ERC) are a recent formulation of CBZ approved by the US Food and Drug Administration in 2004 for the treatment of acute manic and mixed episodes associated with bipolar I disorder. This new formulation was developed to improve dosing convenience and decrease daily fluctuatio...

Hydrocodone is a semisynthetic opioid, which has been used for decades as a short-acting analgesic combined with acetaminophen (or less commonly ibuprofen). Several long-acting, non-acetaminophen-containing hydrocodone formulations are undergoing trials in the US under the auspices of the US Food and Drug Administration, and may be available shortly. This article reviews some of the advantages ...

attention-deficit/hyperactivity disorder (adhd) is a highly heritable neuropsychiatric disorder associated with significant impairments in occu pational, academic, neuropsychological, and social functioning. central nervous system (cns) stimulants are recommended as first-line medication therapy for children. cns stimulants include formulations of methylphenidate and amphetamine derivatives and...

Bupropion hydrochloride is currently available in three formulations: immediate-release, sustained-release, and extended-release (ER). Several published reports exist concerning bupropion's history of inducing seizures in both the immediate- and sustained-release formulations. Although the potential of the ER formulation for causing seizures is noted in the drug's prescribing information, there...